Praxis Precision Medicines Inc (PRAX) concluded trading on Thursday at a closing price of $33.79, with 0.45 million shares of worth about $15.24 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.10% during that period and on April 17, 2025 the price saw a gain of about 13.29%. Currently the company’s common shares owned by public are about 19.42M shares, out of which, 18.74M shares are available for trading.
Stock saw a price change of 18.69% in past 5 days and over the past one month there was a price change of -12.51%. Year-to-date (YTD), PRAX shares are showing a performance of -56.09% which decreased to -35.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $26.70 but also hit the highest price of $91.83 during that period. The average intraday trading volume for Praxis Precision Medicines Inc shares is 542.65K. The stock is currently trading 0.06% above its 20-day simple moving average (SMA20), while that difference is down -30.33% for SMA50 and it goes to -44.63% lower than SMA200.
Praxis Precision Medicines Inc (NASDAQ: PRAX) currently have 19.42M outstanding shares and institutions hold larger chunk of about 105.53% of that.
The stock has a current market capitalization of $681.32M and its 3Y-monthly beta is at 2.69. It has posted earnings per share of -$10.27 in the same period. It has Quick Ratio of 10.77 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRAX, volatility over the week remained 7.23% while standing at 9.08% over the month.
Analysts are in expectations that Praxis Precision Medicines Inc (PRAX) stock would likely to be making an EPS of -3.2 in the current quarter, while forecast for next quarter EPS is -3.19 and it is -12.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -3.69 which is -2.71 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -2.84 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -20.76% while it is estimated to increase by 3.45% in next year. EPS is likely to shrink at an annualized rate of -0.75% for next 5-years, compared to annual growth of 8.54% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on March 03, 2025 offering a Buy rating for the stock and assigned a target price range of between $120 and $105 to it. Coverage by Deutsche Bank stated Praxis Precision Medicines Inc (PRAX) stock as a Buy in their note to investors on February 11, 2025, suggesting a price target of $111 for the stock. On August 05, 2024, Oppenheimer Initiated their recommendations, while on June 24, 2024, Needham Initiated their ratings for the stock with a price target of $145. Stock get a Buy rating from Guggenheim on June 18, 2024.
